Literature DB >> 12409596

Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT.

Burkhard Riemann1, Karsten Papke, Norbert Hoess, Torsten Kuwert, Matthias Weckesser, Peter Matheja, Hansdetlef Wassmann, Walter Heindel, Otmar Schober.   

Abstract

PURPOSE: To compare the accuracy of magnetic resonance (MR) imaging scores with that of 3-(iodine 123)-L-alpha-methyltyrosine ((123)I-IMT) single photon emission computed tomography (SPECT) in the noninvasive grading of untreated gliomas.
MATERIALS AND METHODS: The study comprised 15 patients with low-grade gliomas (grades I-II, according to World Health Organization criteria) and 33 patients with high-grade gliomas (grades III-IV). The lesions were evaluated by using an MR imaging score based on nine criteria. The (123)I-IMT uptake was quantified as the ratio between the amino acid uptake in the tumor and that in the contralateral hemisphere. To test for potentially significant differences in diagnostic performance between contrast material-enhanced MR imaging and (123)I-IMT SPECT, binormal receiver operating characteristic curves were fitted to the data and compared by using the area test.
RESULTS: The accuracy of MR imaging in the noninvasive grading of untreated gliomas was higher than that of (123)I-IMT SPECT (88% vs 79%). However, the difference in diagnostic performance was not significant on the basis of findings at receiver operating characteristic analysis (P >.2). Neither MR imaging nor (123)I-IMT SPECT allowed differentiation between high-grade gliomas (grades III and IV).
CONCLUSION: Although (123)I-IMT uptake is significantly higher in high-grade gliomas than in low-grade gliomas, the performance of (123)I-IMT SPECT adds little to the accuracy of determining tumor grade when MR imaging is performed. Copyright RSNA, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409596     DOI: 10.1148/radiol.2252011431

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  12 in total

1.  Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines.

Authors:  Burkhard Riemann; Otmar Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

2.  EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues.

Authors:  T Vander Borght; S Asenbaum; P Bartenstein; C Halldin; O Kapucu; K Van Laere; A Varrone; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

Review 3.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

4.  Neuroradiological assessment of newly diagnosed glioblastoma.

Authors:  Srini Mukundan; Chad Holder; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

5.  Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-30       Impact factor: 9.236

6.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.

Authors:  M Weckesser; K J Langen; C H Rickert; S Kloska; R Straeter; K Hamacher; G Kurlemann; H Wassmann; H H Coenen; O Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-14       Impact factor: 9.236

7.  Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Nadja Sell; Andrea Schaefer; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-18       Impact factor: 9.236

8.  Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?

Authors:  Gérard Moulin-Romsée; Eduard D'Hondt; Tjibbe de Groot; Jan Goffin; Raf Sciot; Luc Mortelmans; Johan Menten; Guy Bormans; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

9.  Low-grade (WHO II) and anaplastic (WHO III) gliomas: differences in morphology and MRI signal intensities.

Authors:  Max-Ludwig Schäfer; Martin H Maurer; Michael Synowitz; Joost Wüstefeld; Tim Marnitz; Florian Streitparth; Edzard Wiener
Journal:  Eur Radiol       Date:  2013-05-19       Impact factor: 5.315

10.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.

Authors:  Koen Van Laere; Sarah Ceyssens; Frank Van Calenbergh; Tjibbe de Groot; Johan Menten; Patrick Flamen; Guy Bormans; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.